Osteolytic effects of tumoral estrogen signaling in an estrogen receptor-positive breast cancer bone metastasis model

AIM: Estrogen receptor α-positive (ER+) subtypes of breast cancer have the greatest predilection for forming osteolytic bone metastases (BMETs). Because tumor-derived factors mediate osteolysis, a possible role for tumoral ERα signaling in driving ER+ BMET osteolysis was queried using an estrogen (E(2))-dependent ER+ breast cancer BMET model. METHODS: Female athymic Foxn1(nu) mice were inoculated with human ER+ MCF-7 breast cancer cells via the left cardiac ventricle post-E(2) pellet placement, and age- and dose-dependent E(2) effects on osteolytic ER+ BMET progression, as well as direct bone effects of E(2), were determined. RESULTS: Osteolytic BMETs, which did not form in the absence of E(2) supplementation, occurred with the same frequency in young (5-week-old) vs. skeletally mature (16-week-old) E(2) (0.72 mg)-treated mice, but were larger in young mice where anabolic bone effects of E(2) were greater. However, in mice of a single age and across a range of E(2) doses, anabolic E(2) bone effects were constant, while osteolytic ER+ BMET lesion incidence and size increased in an E(2)-dose-dependent fashion. Osteoclasts in ER+ tumor-bearing (but not tumor-naive) mice increased in an E(2)-dose dependent fashion at the bone-tumor interface, while histologic tumor size and proliferation did not vary with E(2) dose. E(2)-inducible tumoral secretion of the osteolytic factor parathyroid hormone-related protein (PTHrP) was dose-dependent and mediated by ERα, with significantly greater levels of secretion from ER+ BMET-derived tumor cells. CONCLUSION: These results suggest that tumoral ERα signaling may contribute to ER+ BMET-associated osteolysis, potentially explaining the greater predilection for ER+ tumors to form clinically-evident osteolytic BMETs.